In her comments to The Lancet, de Ruijter emphasized the Commissioner’s legislative experience and deep understanding of EU law, acknowledging his potential to steer critical health legislation such as the Critical Medicines Act and the European Biotech Act. She highlighted the political complexity surrounding Várhelyi’s appointment, noting how negotiations reflected broader tensions with Hungarian politics rather than his individual competence. 

De Ruijter also underscored the growing influence of the EU in health regulation, particularly through its market powers. “What you want from a Health Commissioner is to address the commercial determinants of health,” she remarked, drawing attention to the delicate balance between health and market interests in Europe. 

Her contributions shed light on the challenges and opportunities ahead for Várhelyi’s tenure, especially in shaping a resilient and equitable EU health ecosystem.